Differences in the ultrasonographic appearance of thyroid nodules after radiofrequency ablation. (3rd May 2021)

• Record Type: Journal Article
• Authors: Wu, Ming‐Hsun; Chen, Kuen‐Yuan; Chen, Argon; Chen, Chiung‐Nien
• Is Part Of: Clinical endocrinology. Volume 95:Number 3(2021)
• Page Start: 489
• Page End: 497
• Publication Date: 2021-05-03
• Subjects: computer‐aid detection -- radiofrequency ablation -- thyroid cancer -- thyroid nodule -- ultrasonography; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.14480
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: Context: Radiofrequency ablation (RFA) is a well‐tolerated approach to treating benign thyroid nodules (TNs), but no index can predict its success. Other than size decrease, little is known about TN appearance on ultrasonography (US) after RFA. Objective: This study aimed to (a) assess the effectiveness of single‐session RFA treatment, (b) determine whether pre‐ablation US characteristics correlate with its effectiveness, and (c) demonstrate TN characteristics on baseline and follow‐up US. Design: Retrospective cohort study among the patients who underwent single‐session RFA for the treatment of benign TNs at a referral medical center between January 2018 and April 2019. Patients: A total of 116 patients (137 nodules) were included in the study. Measurements: Characteristics were quantified using commercial software. TNs were classified into 2015 American Thyroid Association (ATA) sonographic patterns and American College of Radiology Thyroid Imaging Reporting and Data System (ACR‐TI‐RADS) categories. Results: The average volume reduction ratio (VRR) was 74.51% in 1 year (95% confidence interval, 70.63%–78.39%). The only pre‐ablation US feature significantly different between nodules with VRR <50% and VRR >50% was the cyst composition (0.05 vs. 0.02, p ‐value = .02). The VRR and margin change in the first 3 months after ablation were found to be leading indicators significantly correlated to the VRR in 6 months with correlation coefficients ( r ) = .72 and −.28 ( p ‐value < .0001 and = .0008) and VRR in 1 year with r = .65 and −.17 ( p ‐value < .0001 and = .046), respectively. After RFA, more TNs became ATA high suspicion (2.9% vs. 19.7%, p < .0001) and more appeared to be the non‐ATA patterns (12.4% vs. 23.4%, p < .0001). Also, a greater number of post‐RFA TNs were classified as ACR‐TI‐RADS categories 4 and 5 (40.1% vs. 70.1%, p < .0001). Conclusions: Radiofrequency ablation therapy is effective for treating TNs. Pre‐ablation cyst components, 3‐month post‐ablation volume reduction and margin change of TNs were related to the 6‐month and 1‐year response. Clinicians should consider that TNs would appear peculiar on US after RFA, mistakenly suggesting malignant potential.